April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration and Pigment Epithelial Detachment
Author Affiliations & Notes
  • Armada Felix
    Hospital La Paz, Madrid, Spain
  • Pino Cidad
    Hospital La Paz, Madrid, Spain
  • Natalia Pastora
    Hospital La Paz, Madrid, Spain
  • Beatriz Manzano
    Hospital La Paz, Madrid, Spain
  • Irene Rosa
    Hospital La Paz, Madrid, Spain
  • Zurine Del Barrio
    Hospital La Paz, Madrid, Spain
  • Soraya Mediero
    Hospital La Paz, Madrid, Spain
  • Maria Capote
    Hospital La Paz, Madrid, Spain
  • Oriana DAnna
    Hospital La Paz, Madrid, Spain
  • Footnotes
    Commercial Relationships Armada Felix, None; Pino Cidad, None; Natalia Pastora, None; Beatriz Manzano, None; Irene Rosa, None; Zurine Del Barrio, None; Soraya Mediero, None; Maria Capote, None; Oriana DAnna, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3960. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Armada Felix, Pino Cidad, Natalia Pastora, Beatriz Manzano, Irene Rosa, Zurine Del Barrio, Soraya Mediero, Maria Capote, Oriana DAnna; Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration and Pigment Epithelial Detachment. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3960.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To describe the effectiveness of intravitreal aflibercept in pigment epithelial detachment (PED) in patients with neovascular age-related macular degeneration (AMD) as well as the advantages of its use in eyes previously treated with other anti-vascular endothelial growth factor drugs.

Methods: Prospective interventional case series. Patients with neovascular AMD and PED underwent a complete ophthalmologic examination, including best-corrected visual acuity (EDTRS), optical coherence tomography (OCT) and adverse event monitoring. Patients received 2 mg intravitreal aflibercept which included 3 initial loading doses every 6 weeks, followed by an as-needed (pro re nata (PRN)) regimen with defined retreatment criteria.

Results: 30 patients, including 31 eyes, were enrolled in the study and prospectively followed up. There was a statistically significant improvement in PED objectified by OCT. Mean baseline visual acuity was 0.6 LogMAR, and the mean visual acuity at last follow-up was 0.5 LogMAR. Mean central macular thickness at baseline was 385 microns and improved to a mean of 318 microns at last follow-up.

Conclusions: Aflibercept is effective in exudative AMD by the inhibition of choroidal neovascularization, with a longer durability when compared with other drugs. It has excellent outcomes in visual acuity while patients improved their macular morphology by recovering macular thickness while improving PED. Patients treat with aflibercept require fewer injections than patients treat with other drugs, therefore the cost per patient is lower in patients treat with aflibercept. Further follow-up is necessary to verify long-term effects.

Keywords: 412 age-related macular degeneration • 561 injection • 688 retina  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.